


EPIFIX[®]

CARING FOR CHALLENGING CLOSURES WHEN PATIENTS NEED IT MOST



EPIFIX

Protective Barrier

- Supports the healing cascade
- Protects the wound bed to aid in the development of granulation tissue in acute and chronic wounds

Provides a Human Biocompatible Extracellular Matrix (ECM)

- **Structural components:**
Collagen I, III, IV; elastin
- **Cell-binding domains:**
Fibronectin, collagen V, VII
- **ECM-binding domains:**
Proteoglycans, laminin

Retains Regulatory Proteins

- 300+ Regulatory Proteins¹⁻³



- Dehydrated amnion/chorion membrane sheet allograft
- EPIFIX[®] is SMR²T[™] Technology



- *Selective Membrane of Reparative and Reconstructive Tissue*
- Uses PURION[®] patented processing

EPIFIX[®]

Clinical Use Examples

- Comorbid patients with complex defects or delayed healing
- Diabetic foot ulcers (DFUs)
- Venous leg ulcers (VLUs)
- Debridements
- Decubitus ulcers

Product Advantages

- Most level I evidence in placental-based allografts: 6 EPIFIX RCTs
- SMR²T Technology and patented PURION processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)

**Patient Insurance
Verification Team:
855.882.8480**




Patents and patents pending see: www.mimedx.com/patents. EPIFIX, PURION, SMR²T, and MIMEDX are trademarks of MIMEDX Group, Inc. ©2021 MIMEDX Group, Inc. All Rights Reserved. www.mimedx.com EP578.002

EPIFIX is a dehydrated human amnion/chorion membrane allograft. EPIFIX sheets provide a semi-permeable protective barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. EPIFIX provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.¹⁻³

Published Studies	N	Outcomes Observed in Studies
DFU RCT: ^{4,5} EPIFIX vs. Apligraf [®] vs. SOC	EPIFIX: 32 Apligraf: 33 SOC: 35	Complete wound closure: 85% at 4 weeks (EPIFIX vs. Apligraf $p=0.001$; EPIFIX vs. SOC $p=0.001$) 95% at 6 weeks (EPIFIX vs. Apligraf $p=0.0006$; EPIFIX vs. SOC $p=0.0001$) 97% at 12 weeks (EpiFix vs. Apligraf $p=0.0001$; EPIFIX vs. SOC $p=0.0001$)
VLU Multicenter RCT: ^{6,7} EPIFIX vs. SOC	EPIFIX: 52 SOC: 57	Complete wound closure (Per Protocol): 60% at 12 weeks ($p=0.0128$) 71% at 16 weeks ($p=0.0065$)

HOPD & WCC* Ordering Information

Item #	Size & Description
GS-5180	18 mm disk
GS-5220	2 cm x 2 cm sheet
GS-5230	2 cm x 3 cm sheet
GS-5240	2 cm x 4 cm sheet
GS-5340	3 cm x 4 cm sheet
GS-5440	4 cm x 4 cm sheet
GS-5560	5 cm x 6 cm sheet
GS-5770	7 cm x 7 cm sheet
Item #	Size & Description
ES-2300	2 cm x 3 cm mesh sheet
ES-3300	3.5 cm x 3.5 cm mesh sheet
ES-4400	4 cm x 4.5 cm mesh sheet
ES-5500	5 cm x 5.5 cm mesh sheet



*Q Code: 4186

Apligraf is a registered trademark of Organogenesis

SMR²T & Purion

REFERENCES: **1.** Koob TJ, Lim JJ, Masee M, Zabeck N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater.* 2014;102(6):1353-1362. **2.** Lei J, Priddy LB, Lim JJ, Masee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. *Adv Wound Care (New Rochelle).* 2017;6(2):43-53. **3.** MM-RD-00086, Proteome Characterization of PURION Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and PURION PLUS Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. **4.** Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. *Int Wound J.* 2015;12(6):724-732. **5.** Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. *Int Wound J.* 2016;13(2):272-282. **6.** Bianchi C, Cazzell S, Vajser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EPIFIX[®]) allograft for the treatment of venous leg ulcers. *Int Wound J.* 2018;15(1):114-122. **7.** Bianchi C, Tettelbach W, Istwan N, et al. Variations in study outcomes relative to intention-to-treat and per-protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft. *Int Wound J.* 2019;16(3):761-767.

866.477.4219 • customerservice@mimedx.com